Corporate versus public interests: Community responsibility to defend scientific integrity

International Journal of Occupational and Environmental Health

Volumn 17, Issue 2, 2011, Pages 181-185

  Egilman, David S ^a   Druar, Nicholas M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; ETHICS; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL RESEARCH; NOTE; PUBLICATION; PUBLISHING; WRITING;

AUTHORSHIP; BIOMEDICAL RESEARCH; DISCLOSURE; DRUG INDUSTRY; EDITORIAL POLICIES; HUMANS; PERIODICALS AS TOPIC;

EID: 79955090092     PISSN: 10773525     EISSN: None     Source Type: Journal    
DOI: 10.1179/oeh.2011.17.2.182     Document Type: Article

References (48)

1. Gotzsche PC, Kassirer JP, Woolley KL, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Med. Feb 3 2009;6(2):e23.
2. Wnukiewicz-Kozlowska A. Legal and ethical aspects of ghostwriting in medicine. Arch Immunol Ther Exp (Warsz). Feb 2011;59(1):1-9.
3. Langdon-Neuner E. Medical Ghostwriting. Mens Sana Monogr. 2008;6(1): 257-273.
4. Flanagin A, Carey LA, Fontanarosa PB, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA. Jul 15 1998;280(3):222-224.
5. Mowatt G, Shirran L, Grimshaw JM, et al. Prevalence of honorary and ghost authorship in Cochrane reviews. Jama. Jun 5 2002;287(21):2769-2771.
6. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. Apr 16 2008;299(15):1800-1812.
7. Sismondo S, Nicholson SH. Publication planning 101. J Pharm Pharm Sci. 2009;12(3):273-279.
8. Moffatt B, Elliott C. Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med. Winter 2007;50(1):18-31.
9. Fugh-Berman AJ, Dodgson S. Ethical considerations of publication planning in the pharmaceutical industry. Open Medicine. 2008;2(4).
10. Nahai F. Ghostwriting: stringent disclosure policies take aim at authorship abuses. Aesthet Surg J. Mar 2010;30(2): 265-266.
11. Eaton L. Medical editors issue guidance on ghost writing. Bmj. Apr 30 2005;330(7498):988.
12. Carey TS, Williams JW, Jr., Oldham JM, et al. Gabapentin in the treatment of mental illness: the echo chamber of the case series. J Psychiatr Pract. Mar 2008; 14 Suppl 1:15-27.
13. Williams JW, Jr., Ranney L, Morgan LC, Whitener L. How reviews covered the unfolding scientific story of gabapentin for bipolar disorder. Gen Hosp Psychiatry. May-Jun 2009;31(3):279-287.
14. Ziemba KS, O'Carroll CB, Drazkowski JF, et al. Do antiepileptic drugs increase the risk of suicidality in adult patients with epilepsy?: A critically appraised topic. Neurologist. Sep 2010; 16(5):325-328.
15. Fullerton CA, Busch AB, Frank RG. The rise and fall of gabapentin for bipolar disorder: A case study on offlabel pharmaceutical diffusion. Med Care. Apr 2010;48(4):372-379.
16. Appendix A-2008 Financial Report. In: Pfizer, ed2008.
17. Baethge C. On ghost authorship and reviews: the 6th International Congress on Peer Review and Biomedical Publication. Dtsch Arztebl Int. Nov 2009; 106(45):731-732.
18. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med. Sep 2007;4(9):e286.
19. Quan SF. Guests and ghosts begoneguest authorship and ghostwriting and the Journal of Clinical Sleep Medicine. J Clin Sleep Med. Jun 15 2008;4(3):203.
20. Barbour V. How ghost-writing threatens the credibility of medical knowledge and medical journals. Haematologica. Jan;95(1):1-2.
21. Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Med. Sep 2009;6(9):e1000156.
22. (ICMJE) ICoMJE. Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Phildelphia, PA: ICMJE; 2007.
23. Ghost writing initiated by commercial companies. J Gen Intern Med. Jun 2005;20(6):549.
24. Bosch X. Treat ghostwriting as misconduct. Nature. Jan 27 2011;469(7331): 472.
25. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. Nov 23 2000;343(21):1520-1528, 1522 p. following 1528.
26. Bombardier C, Laine L, Burgos-Vargas R, et al. Response to expression of concern regarding VIGOR study. N Engl J Med. Mar 16 2006;354(11):1196-1199.
27. Abel B. Re: Comments about the new NEJM. org. In: Egilman DS, ed2011.
28. Medicine NEJo. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis.[Accessed February 20, 2011.] Available at: http://www.nejm.org/doi/full/10.1056/NEJM200011233432103.
29. McHenry LB, Jureidini JN. Industrysponsored ghostwriting in clinical trial reporting: a case study. Account Res. Jul-Sep 2008;15(3):152-167.
30. Jureidini JN, McHenry LB. Conflicted medical journals and the failure of trust. Account Res. Jan 2011;18(1): 45-54.
31. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. Jun 2005;30(6):1204-1215.
32. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. Jama. Apr 16 2008;299(15):1813-1817.
33. Newman M. The rules of retraction. Bmj.341:c6985.
34. Murray S, Brophy J, Palepu A. Open Medicine's ghost and guest authorship policy. 2010.
35. Statistical review and evaluation: Antiepileptic drugs and suicidality. Office of Biostatistics, Office of Translational Services, Center for Drug Eval uation and Research, Food and Drug Administration, US Department of Health and Human Services; 2008 May 23 Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf. Accessed March 8, 2011.
36. Jureidini J, McHenry L, Mansfield P. Clinical trials and drug promotion: selective reporting of study 329. International Journal of Risk and Safety in Medicine. 2008;20(1):8.
37. Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med. Nov 23 2009;169(21):1976-1985.
38. Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM. Persistence of cardiovascular risk after rofecoxib discontinuation. Arch Intern Med. Dec 13 2010;170(22):2035-2036.
39. Egilman D, Presler A. Report of specific cardiovascular outcomes of the ADVANTAGE trial. Ann Intern Med. 2006;144(16):1.
40. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? Bmj. Jan 20 2007;334(7585): 120-123.
41. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. Apr 16 2008;299(15):1800-1812.
42. Lundh A, Barbateskovic M, Hrobjartsson A, Gotzsche PC. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue-cohort study. PLoS Med.7(10): e1000354.
43. Anekwe TD. Profits and plagiarism: the case of medical ghostwriting. Bioethics. Jul 2010;24(6):267-272.
44. Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med. Aug 19 2008;149(4): 251-258.
45. Thomas L. Judge Rules Drug Documents Must Be Returned to Eli Lilly. The New York Times. February 14, 2007.
46. Brandeis LD. What Publicity Can Do. Other People's Money. 1914.
47. Evans D. Big Pharma's Crime Spree. Bloomber Markets. December 2009.
48. Egilman D, Ardolino E. The Pharmaceutical Industry, Disease Industry: A Pescription for Illness and Death. In: H. WW, ed. The bottom line or public health: Tactics corporations use to influence health and health policy and what we can do to counter them. Oxford; New York: Oxford University Press; 2010:xix, 570 p.